share_log

HC Wainwright & Co. Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.4

HC Wainwright & Co. Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.4

HC Wainwright & Co.以买入评级开始对Acasti Pharma进行报道,宣布目标价为2.4美元
Benzinga Real-time News ·  2022/12/15 20:44

HC Wainwright & Co. analyst Oren Livnat initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces Price Target of $2.4.

HC Wainwright&Co.分析师Oren Livnat以买入评级启动对Acasti Pharma(纳斯达克:ACST)的报道,并宣布目标价为2.4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发